荣昌生物制药（烟台）股份有限公司（H股代码：09995；A股代码：688331）于2026年1月7日更新发布截至2025年12月31日的股份变动月报表。报告期内，公司注册资本与已发行股份总数均维持不变。
\n\n根据公告，报告期末公司H股注册资本为208,581,239股，A股注册资本为355,129,004股，二者合计注册资本为563,710,243元人民币，较上月无增减变动。已发行H股为208,581,239股，已发行A股为355,129,004股，均无新增发行或回购注销。
\n\n在股权激励方面，公告披露了公司2022年及2023年A股股票激励计划的授予与失效情况，当前处于限制性股票激励计划项下的尚未归属或仍有效的A股合计有若干数量，但报告期内并无实际新增发行或从库藏股票转让的情况。
\n\n截至本月末，公司无购回或注销活动，股本总数维持稳定。公司同时确认，已遵守香港联合交易所有限公司上市规则及其他适用法律法规。公告由公司董事王威东签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.